uveal melanoma
Oncology · 2023–2023
1decision
1medicine
1carried consumer input
10individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tebentafusp Treatment of HLA-A*02:01-positive adult patients with advanced (unresectable or metastatic) uveal melanoma. | Sep 2023 | Recommended with restriction | 10 individuals Skin Cancer Advocacy Network · Rare Cancers Australia · Australasian Ocular Melanoma Alliance · Melanoma Patients Australia · Ocumel Australia · Medical Oncology Group |
Who spoke
Skin Cancer Advocacy Network · Rare Cancers Australia · Australasian Ocular Melanoma Alliance · Melanoma Patients Australia · Ocumel Australia · Medical Oncology Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.